The STAT Summit, our biggest event of the year, is next week. Let me quickly give you three reasons why I think anyone in biotech or health care would benefit from signing up to be there (in person or virtually) while there is still space.
The News. Our sessions are ripped from the health care headlines. This week we added a new session on the upheavals at the NIH, moderated by Anil Oza, among the STAT reporters who have been so on top of the changes in government funding of science. It will feature Eric Green, the former head of the National Human Genome Research Institute, whose ouster was first reported by STAT; Jeremy Berg, who has himself been a nexus of information on the upheaval; and Mallory Harris, a data scientist tracking the impact of scientific funding. Pay attention to our session on the CDC and FDA, as well.
STAT Journalists. Last night, STAT's Lev Facher won the Loeb Award for Explanatory Reporting, one of the highest honors in business journalism, for his series "The War On Recovery," which laid out the reasons the U.S. denies lifesaving medicines to people with opioid use disorder. Next Thursday, Lev will interview Stephen M. Taylor, the president of the American Society of Addiction Medicine, on stage. Our seasoned journalists are the catalyst for the magic that will happen on the news.
The Audience. Live events feed on the quality of the people in the room. This is one of the best attendee lists I've seen in the decade-plus I've been putting together these types of conferences. Expect to see CEOs, former government officials, and investors and top scientists attending and asking questions.
We have an amazing roster of speakers this year, from the family of Baby KJ to a panel of top pharma CEOs to Doctor Mike to Joe Kennedy III to executives from two of biotech's biggest company builders, not to mention the president of the AMA and a slew of former government officials. I promise, being in the room will deliver dividends throughout the coming year.
I hope to see you in Boston!
Matt Herper
Editorial Director of Events, STAT
LAST CALL TO ATTEND IN BOSTON
Limited in-person seats are still available
General admission is 90% sold out — we've added a limited number of seats! Secure your pass now.
No comments